

APPLIED DNA SCIENCES INC  
Form 8-K  
October 23, 2013

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): October 17, 2013**

**Applied DNA Sciences, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**

(State or Other Jurisdiction  
of Incorporation)

**002-90539**

(Commission File Number)

**59-2262718**

(IRS Employer

Identification No.)

**50 Health Sciences Drive**

**Stony Brook, New York 11790**

(Address of Principal Executive Offices) (Zip Code)

**631-240-8800**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 40.14d - (b))

£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e - (c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On October 17, 2013, Dr. James A. Hayward, Chairman, Chief Executive Officer and President of Applied DNA Sciences, Inc. (the “Company”) and Mr. Ming-Hwa Liang, Chief Technology Officer and Secretary of the Company were each granted options by the Board of Directors to purchase 50,000,000 and 3,000,000 shares of the Company’s Common Stock, \$.001 par value, respectively, pursuant to the Company’s 2005 Incentive Stock Plan. The options have a term of five years and an exercise price of \$.097 per share.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Applied DNA Sciences,  
Inc.**  
(Registrant)

By: /s/ James A. Hayward  
James A. Hayward  
Chief Executive Officer

Date: October 23, 2013